M. Scot Roberts - Jun 29, 2022 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role: Chief Scientific Officer
Signature: /s/ Richard Eisenstadt, as Attorney-in-Fact
Stock symbol: ALT
Transactions as of: Jun 29, 2022
Transactions value $: -$51,345
Form type: 4
Date filed: 6/30/2022, 04:05 PM
Previous filing: Jun 28, 2022
Next filing: Jul 5, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$14.2K	+5.46K	+30.86%	$2.60	23.2K	Jun 29, 2022	Direct
transaction	ALT	Common Stock, par value $0.0001	Sale	-$65.5K	-5.46K	-23.58%	$12.00	17.7K	Jun 29, 2022	Direct	F1, F2
holding	ALT	Common Stock, par value $0.0001						15	Jun 29, 2022	Shares held by spouse of Reporting Person

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALT	Stock Options (option to buy)	Options Exercise	$0	-5.46K	-29.96%	$0.00	12.8K	Jun 29, 2022	Common Stock, par value $0.0001	5.46K	$2.60	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.0050, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3	Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.